SLC5A2 and diabetes mellitus: A compelling confirmation of this hypothesis comes from a clinical report describing the use of tofogliflozin, an SGLT2 inhibitor, which enabled the successful discontinuation of previously administered erythropoiesis-stimulating agents (ESAs) in patients with diabetes.